Brodalumab: First Global Approval

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

(2016) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis

(2016) Philip J. Mease et al.   JOURNAL OF RHEUMATOLOGY

Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis

(2016) Y. Umezawa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Use of brodalumab for the treatment of psoriasis and psoriatic arthritis

(2015) Dario N Kivelevitch et al.   Immunotherapy

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

OP0118 Clinical Overview of A Cohort of 87 Italian Patients with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus Infection (PANDAS)

(2014) F. Falcini et al.   ANNALS OF THE RHEUMATIC DISEASES

Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies

(2014) Christopher J. Endres et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody

(2014) C. B. Russell et al.   JOURNAL OF IMMUNOLOGY

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial

(2012) Kim A. Papp et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE